^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Gastric Cancer |
| Drug: | Insegia (PAS) (Gastrin-17 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Role of an anti-gastrin vaccine (PAS) alone and in combination with a PD-1 antibody on growth and metastases of gastric cancer.
Published date:
01/18/2022
Excerpt:
Gastrin, CCK-BR, and PD-L1 expression were confirmed by qRT-PCR in the gastric cancer cells...PAS monotherapy (P = 0.023) or PAS in combination with PD-1 Ab (P = 0.0003) resulted in significantly slowed tumor growth and with no metastases observed...PAS vaccination improves the effectiveness of PD-1 Ab therapy in part by decreasing tumor fibrosis...This study suggests that addition of PAS to immune checkpoint antibody therapy in gastric cancer may be beneficial.
Secondary therapy:
anti-PD-1 antibody
DOI:
10.1200/JCO.2022.40.4_suppl.334